Durvalumab after chemoradiotherapy in non-small cell lung cancer harboring driver gene mutation/translocation: a retrospective multicenter study (HOT2101)
Not Applicable
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000048100
- Lead Sponsor
- Hokkaido Lung Cancer Clinical Study Group(HOT)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 88
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who were deemed inappropriate for enrollment by investigators
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To provide insights into outcomes of durvalumab consolidation efficacy and safety in non-small cell lung cancer harboring driver gene mutation/translocation.
- Secondary Outcome Measures
Name Time Method 1. progression free survival 2. overall survival